<DOC>
	<DOCNO>NCT00191373</DOCNO>
	<brief_summary>This phase II trial include Gemcitabine 1,250mg/m2 administer approximately 30 minute day 1 8 , every 21 day Trastuzumab 8 mg/kg IV administer 90 minute day 1 first cycle , 6mg/kg 30 minute infusion administer subsequent cycle .</brief_summary>
	<brief_title>A Trial HER2 Positive Breast Cancer Patients With Metastatic Disease</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must histologically cytologically confirm invasive breast cancer , stage IV disease Tumors test IHC must 3+ positive HER2 overexpression . Tumors test FISH must positive specific FISH assay genetic amplification HER2 . Tumors 3+ IHC negative FISH assay ineligible Patients must measurable disease Patients may NOT receive prior chemotherapy prior trastuzumab therapy metastatic breast cancer . Patients may receive prior chemotherapy and/or hormonal therapy early stage breast cancer , include taxanebased chemotherapy regimen . Patients may NOT receive trastuzumab adjuvant set unless disease free interval completion trastuzumab time relapse great 12 month . Patients prior gemcitabine chemotherapy adjuvant trastuzumab le 12 month disease free interval Patients know leptomeningeal carcinomatosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>